Eli Lilly and Company
Eli Lilly and Company (LLY) Financial Performance & Income Statement Overview
Explore the financials of Eli Lilly and Company (LLY), including yearly and quarterly data on income, cash flow, and balance sheets.
Eli Lilly and Company (LLY) Income Statement & Financial Overview
Analyze Eli Lilly and Company’s LLY earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $12.73B | $13.53B | $11.44B | $11.30B |
| Cost of Revenue | $2.22B | $2.40B | $2.17B | $2.17B |
| Gross Profit | $10.50B | $11.13B | $9.27B | $9.13B |
| Gross Profit Ratio | $0.83 | $0.82 | $0.81 | $0.81 |
| R&D Expenses | $2.73B | $3.02B | $2.73B | $2.71B |
| SG&A Expenses | $2.36B | $2.31B | $1.98B | $2.003B |
| Operating Expenses | $5.10B | $5.33B | $4.72B | $4.71B |
| Total Costs & Expenses | $7.32B | $7.74B | $6.89B | $6.88B |
| Interest Income | $48.30M | $44.30M | $47.80M | $37.30M |
| Interest Expense | $243.70M | $224.70M | $192.70M | $183.60M |
| Depreciation & Amortization | $462.80M | $484.80M | $466.80M | $414.40M |
| EBITDA | $4.16B | $5.75B | $2.25B | $4.12B |
| EBITDA Ratio | $0.33 | $0.42 | $0.20 | $0.36 |
| Operating Income | $5.41B | $5.80B | $4.55B | $4.42B |
| Operating Income Ratio | $0.42 | $0.43 | $0.40 | $0.39 |
| Other Income/Expenses (Net) | -$1.95B | -$759.10M | -$2.96B | -$901.30M |
| Income Before Tax | $3.46B | $5.04B | $1.59B | $3.52B |
| Income Before Tax Ratio | $0.27 | $0.37 | $0.14 | $0.31 |
| Income Tax Expense | $696.80M | $628.90M | $618.10M | $550.20M |
| Net Income | $2.76B | $4.41B | $970.30M | $2.97B |
| Net Income Ratio | $0.22 | $0.33 | $0.08 | $0.26 |
| EPS | $3.07 | $4.91 | $1.08 | $3.29 |
| Diluted EPS | $3.06 | $4.88 | $1.07 | $3.28 |
| Weighted Avg Shares Outstanding | $897.99M | $897.54M | $901.00M | $900.90M |
| Weighted Avg Shares Outstanding (Diluted) | $900.60M | $903.16M | $905.00M | $904.20M |
Over the last four quarters, Eli Lilly and Company's revenue moved from $11.30B in Q2 2024 to $12.73B in Q1 2025. Operating income in Q1 2025 was $5.41B, with a strong operating margin of 42%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Eli Lilly and Company remained robust at $4.16B, reflecting operational efficiency. Net income dropped to $2.76B, with an EPS of $3.07. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan